Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Innovative Imperial spin-out biopharmaceutical company teams up with BioVectra

PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, today announced that it has signed a manufacturing and bilateral representation agreement with BioVectra dcl, a Canadian biopharmaceutical company that supplies specialty chemicals and contract manufacturing services to the pharmaceutical and biotechnology industry.

The agreement, which follows hard on the heels of PolyTherics’ recent successful fundraising of over £2 million, will see BioVectra manufacturing high quality cGMP MPEG reagents to support clients’ clinical development of PolyTherics’ novel PEGylation technology. BioVectra will also market the PEGylation technology to its client base in North America.

PolyTherics has developed patent-protected proprietary technologies and expertise in the modification of drugs to improve their performance. The Company’s innovative PEGylation technology, known as TheraPEG, can extend the half-life of novel and existing protein drugs. The TheraPEG approach produces an improvement in biological activity and a higher yield than the existing PEGylation technologies. This means that drugs, such as Interferon, stay active in the body for longer, enabling longer periods between doses. Patients can therefore be treated less often, with fewer side-effects and at lower cost.

The market for traditional PEGylation has expanded considerably and PolyTherics’ TheraPEG technology is positioned both to address existing markets and open new markets, particularly in the antibody field. PolyTherics already has revenue-generating development contracts in place with several companies and is in discussion with a number of other parties.

Dr Keith Powell, CEO of PolyTherics, said: “We are delighted to have signed this agreement with BioVectra, who offer access to specialist custom polymer chemistry capabilities, a patented MPEG purification process and scaled manufacturing systems –the key components that are needed to support clients of our TheraPEG™ technology.

“We are currently in discussion with a number of biogeneric and pharmaceutical companies in Europe and the USA and there is significant interest in downstream applications for our TheraPEG technology. This agreement with BioVectra means that we can work with a highly competent manufacturer who will supply the highest quality MPEGs to meet our clients’ needs and comply with FDA standards. So we now have the tools to take our TheraPEG™ technology from the laboratory into the feasibility testing and manufacturing stages.”

Stephen Ball, Business Development Representative for BioVectra, said: “We are pleased to be working with PolyTherics to support the development of their innovative and important site specific TheraPEG technology. We look forward to deploying our capabilities in the manufacturing of high quality cGMP MPEG reagents to assist PolyTherics’ clients through clinical development of therapeutic proteins into post approval commercialization.”

Dale Zajicek, Chief Operating Officer of BioVectra, said: “We remain committed to supporting our PEGs business initiatives with technology that creates true value for our customers and their patients. The PolyTherics agreement is a clear example of this commitment.”

Margaret Henry | alfa
Further information:

More articles from Life Sciences:

nachricht Don't Give the Slightest Chance to Toxic Elements in Medicinal Products
23.03.2018 | Physikalisch-Technische Bundesanstalt (PTB)

nachricht North and South Cooperation to Combat Tuberculosis
22.03.2018 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>